Prevalence of hyperglycemia and its impact on mortality among HIV patients in Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Assessment of HCV screening and linkage to care modalities within the Georgia’s national Hepatitis C elimination program and designing the most optimal models for reaching the elimination targets

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Molecular epidemiology of Hepatitis C virus isolated from patients with newly diagnosed HCV infection in 2017-2021

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Surveillance of recent HIV infection in Georgia, 2018-2020

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

“ALT flare” implication into further TDF-containing chronic hepatitis B therapy effectiveness among people living with HIV

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

A series of cases of HIV and acute Hepatitis B coinfection – treatment issues

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Progress in roll-out of generic dolutegravir-based treatment in Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Avidity of antibodies to Hepatitis C virus in persons with newly diagnosed HCV infection

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Latvia on its’ way to achieve WHO plan to eliminate Hepatitis C by 2030

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Co-infections with Hepatitis virus B and C among patients with human immunodeficiency virus in a regional center of HIV/AIDS from northeastern Romania

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Hepatitis C virus treatment response to sofosbuvir/ledipasvir among adolescents coinfected with HIV and HCV: Real world data from Ukraine

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Associations between HLA Class II- DRB1 Alleles with susceptibility to Viral Hepatitis B and C in patients with HIV infection

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Occult HBV infection and two clinical cases with malignant comorbidities

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Randomized control trial of home-based Hepatitis C self-testing in key populations in Georgia

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Prevalence of Hepatitis among the general population in Botswana from the STI microbial survey of 2017/2018

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Simplified ART regime on the background of multi-allergy in an elderly HIV-infected patient

Central and Eastern European Meeting on Viral Hepatitis and HIV 2021

Virological Failures and Genotypic Resistance in Children and Adolescents Randomised to Dolutegravir-Based ART vs. Standard-of-Care in the ODYSSEY Trial

International Workshop on HIV Pediatrics 2021

Early Infant Diagnosis of HIV and Linkage to Antiretroviral Therapy in the Context of COVID-19 in Fifteen Sub-Saharan African Countries

International Workshop on HIV Pediatrics 2021

Pediatric and Adolescent HIV Viral Load Coverage and Suppression Rates in the Context of the COVID-19 Pandemic in 14 Sub-Saharan African PEPFAR Countries in 2019 and 2020

International Workshop on HIV Pediatrics 2021

Efficacy, Safety and Tolerability of Guideline-Recommended ARVs from Pediatric Clinical Trials: A Systematic Review

International Workshop on HIV Pediatrics 2021

Once-Daily Integrase Inhibitor (Insti) With Boosted Darunavir is Non-Inferior to Standard of Care in Virogically Suppressed Children, Week 48 Results of the Smile PENTA-17 Trial

International Workshop on HIV Pediatrics 2021

B/F/Taf in Virologically Suppressed Adolescents and Children: Two-Year Outcomes in 6 to <18 Year Olds And Six-Month Outcomes in Toddlers

International Workshop on HIV Pediatrics 2021

Long-term Safety & Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (E/C/F/TAF) Single-Tablet Regimen in in Children and Adolescents Living with HIV

International Workshop on HIV Pediatrics 2021

Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 kg: Preliminary Results from IMPAACT 2019

International Workshop on HIV Pediatrics 2021